CureMatch
×
  • Physicians
    • Patients
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact

Tech Entrepreneur Phil Trubey Makes Sizeable Investment in CureMatch

Tech Entrepreneur Phil Trubey Makes Sizeable Investment in CureMatch
Press Releases

CureMatch receives a new investment by Tech Entrepreneur Phil Trubey on the heels of San Diego Venture Group’s selection of CureMatch as a venture-ready company.

SAN DIEGO, CA – June 14, 2017 –CureMatch, a digital health company that guides oncologists in the selection of advanced cancer therapies, today announced that Phil Trubey had joined a team of investors as part of a bridge round to Series A financing.

Phil Trubey founded Websense, Inc. (now Forcepoint), a global leader in protecting organizations from the cyber-attacks and data theft. Websense was acquired by Raytheon in 2015 for $1.8 billion.

CureMatch is the only company to offer a report that guides oncologists in the selection of personalized combination therapies, using supercomputing and the latest discoveries in genomics and proteomics. CureMatch analyzes more than 4.5 million different drug combinations to find and rank the most advanced cancer treatments, customized specifically for the individual patient. The resulting report provides actionable knowledge and insight to the oncologist, facilitating the use of genomics in cancer treatment.

“I’ve been following CureMatch’s remarkable progress over the past several months, and am very impressed by their team and their unique technology,” said Phil Trubey. “I believe that this company is going to have a tremendous impact on how cancer is treated.”

“Phil and I both started web companies in San Diego from scratch, and both went public,” stated CureMatch CEO Blaise Barrelet, who founded the web analytics industry pioneer WebSideStory, which had a successful IPO in 2004. “We both believe that CureMatch has the potential to be bigger than WebSideStory and Websense.”

Phil Trubey joins other seed investors in CureMatch, including Mike Norman (San Diego Supercomputer Center), Susan Tharp (NCSA Mosaic), Analytics Ventures, Hera Fund, Blaise Barrelet (CureMatch), and many others.

CureMatch was recently selected by the San Diego Venture Group as one of its 2017 Cool Companies. SDVG’s list of Cool Companies are those determined to be “venture-ready” and among the “fastest-growing, most exciting startups in Southern California.” In the past two months, CureMatch has been featured on the KUSI Evening News in its weekly segment “Health Living”, as well as Xconomy, the San Diego Business Journal, Hatch Magazine, NBC 7 San Diego, and many other media outlets. Validation of the CureMatch technology and its core principles have been demonstrated through recent case studies and publications from CureMatch and its co-founders.

CureMatch will be showcased at the SDVG Cool Companies Reception on June 15 and at Startup Week’s Friday Night Startup Festival on June 23. CureMatch will also be present at RESI San Diego on June 19 and the BIO International Convention in San Diego on June 19-22. Later in the summer, CureMatch co-founder and UCSD oncologist Dr. Razelle Kurzrock will serve as a panelist at the Precision Medicine Leaders Summit in San Diego on August 21-24. The CureMatch team will also attend San Diego Venture Group’s Venture Summit in San Diego on August 30, and BIOCOM’s DeviceFest & Digital Health Summit in Carlsbad, CA, also on August 30.

About CureMatch

CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. www.curematch.com

 

Media Contact
Martin Culjat

(858)859-2873
press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

  • Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™

    PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...

  • How Precision Medicine Can Help You

    Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...

  • 64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19

    Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Validation

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

  • CureMatch at WIN Symposium 2018 Winning the War against Cancer with Precision Oncology

    SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results...

  • Personalized Drug Combinations Can Lead to Better Results for Cancer Patients

    A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle...

Archives

  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 859-2873

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer Dec 15

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials Dec 13

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy Oct 19

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
FAQ | Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data